

Sebastiano Galantucci,¹ Federica Agosta,¹ Tanja Stojković,³ Silvia Basaia,¹ Iva Stanković,³ Elka Stefanova,³ Vladimir S. Kostic,³ Massimo Filippi.^{1,2}

¹Neuroimaging Research Unit, and ²Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; ³Clinic of Neurology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

INTRODUCTION AND OBJECTIVE

Investigation of the brain wiring architecture is a powerful approach in the examination of the pathogenic mechanisms of neurodegenerative disease. This study investigates the relationship between functional brain networks and the chronic dopaminergic therapy dose quantified as levodopa equivalent daily dose (LEDD) in a large population of Parkinson's disease (PD) patients without dementia.

MATERIALS AND METHODS

- 170 PD patients (116 without cognitive impairment) performed resting state functional MRI (fMRI) using a 1.5 T MR scanner.
- All patients underwent a comprehensive clinical and neuropsychological evaluation including tests that assess different cognitive domains: attention and working memory, executive functions, memory, language, and visuospatial functions. According to the MDS Task-force criteria (Litvan, et al., 2012), PD-MCI patients had multi-domain MCI with 24% having impairment of attention and working memory, 74% of executive functions, 64% of memory, 74% of language and 80% of visual spatial abilities.
- Graph theory analysis was used to measure the global topological properties of functional brain networks in patients and controls.
- Cortical and subcortical brain areas (i.e., the nodes of the connectome) were identified on volumetric T1-weighted images using Freesurfer.
- Functional connectome was reconstructed for each subject using two thresholds, i.e., $r=0.2$ ($p=0.0045$) and $r=0.3$ ($p<0.0001$).
- Measures of functional connectivity (FC) obtained at both thresholds were correlated with the LEDD of each subject using Spearman's partial correlation.
- UPDRS III score, disease duration and age were considered as nuisance variables.

Table 1. Demographic and clinical findings of PD patients and healthy controls.


| | Healthy controls | All PD | p* | PD-MCI | All PD-ncog | PD-MCI vs controls | All PD-ncog vs controls |
|---|-------------------|----------------------|------|------------------------|------------------------|--------------------|-------------------------|
| Number | 41 | 170 | | 54 | 116 | - | |
| Right-handed | 41 | 162 | 0.37 | 52 | 110 | 0.46 | 0.14 |
| Men/women | 15/26 | 100/70 | 0.01 | 29/25 | 71/45 | 0.1 | 0.01 |
| Age at MRI, ys | 63 ± 8 (49-77) | 62 ± 8 (39-83) | 0.68 | 64 ± 9 (39-81) | 61 ± 8 (43-83) | 0.48 | 0.33 |
| Education, ys | 13.5 ± 2.9 (8-18) | 12.4 ± 2.6 (8-20) | 0.01 | 10.9 ± 2.4 (8-16) | 13.1 ± 2.4 (8-20) | <0.001 | 0.19 |
| Age at onset, ys | - | 57.2 ± 9.1 (31-76) | - | 58.2 ± 9.3 (38-76) | 56.8 ± 9.2 (31-74) | - | - |
| Disease duration, ys | - | 5.1 ± 5.2 (1-26) | - | 6.2 ± 4.9 (1-22) | 5.4 ± 5.4 (1-26) | - | - |
| UPDRS III | - | 28.8 ± 16.1 (5-76) | - | 37.2 ± 16.3 (12-76) | 24.9 ± 14.4 (5-61) | - | - |
| UPDRS total | - | 43.5 ± 21.5 (7-102) | - | 55.8 ± 21.9 (16-102) | 37.9 ± 18.9 (7-86) | - | - |
| H&Y | - | 1.7 ± 0.8 (1-4) | - | 2.1 ± 0.9 (1-4) | 1.7 ± 1 (1-3) | - | - |
| Motor phenotype, tremor dominant/rigid akinetic | - | 69/95 | - | 23/29 | 46/66 | - | - |
| Asymmetry, asymmetric/symmetric | - | 163/7 | - | 52/2 | 111/5 | - | - |
| Side of onset, right/left/symmetric | - | 103/61/5 | - | 31/21/1 | 72/40/4 | - | - |
| LEDD | - | 522 ± 425.4 (0-1930) | - | 690.5 ± 433.8 (0-1560) | 443.6 ± 399.6 (0-1930) | - | - |

Numbers are mean ± standard deviation (range) or number. P values refer to ANOVA models, followed by post-hoc pairwise comparisons. Abbreviations: H&Y: Hoehn & Yahr scale; LEDD: Levodopa Equivalent Daily Dose; PD-MCI: PD patients with mild cognitive impairment; PD-ncog: PD patients with no cognitive impairment; UPDRS: Unified Parkinson's Disease Rating Scale; ys: years.

Resting-state fMRI processing


- Pre-processing (realignment, normalization, linear detrend, band-pass filtering 0.01-0.08 Hz).
- Extraction of average fMRI time series from the 68 cortical regions of the Desikan atlas plus the basal ganglia.
- Assessment of bivariate Pearson's correlation coefficients between each pair of time series, which results in a connectivity matrix for each study subject.

Figure 1. Functional connectome: illustration of the procedure for functional connectome generation and analysis.



RESULTS

Figure 2. Functional connectome correlation analysis: At $p=0.0045$, we observed a positive correlation of LEDD with a distributed network including regions of prefrontal cortex, such as the bilateral inferior and middle frontal gyri, and the orbitofrontal cortex as well as anterior cingulate gyrus. There was also a positive correlation with FC between the bilateral striatum and temporal structures such as the right superior temporal gyrus and right transverse temporal lobe. LEDD positively correlated with another posterior network involving bilateral visual regions such as the pericalcarine and lateral occipital cortex. On the other hand, a large bilateral FC network negatively correlated with LEDD and included precuneus, inferior parietal and supramarginal gyri, paracentral lobule as well as fusiform gyrus, middle temporal gyrus and superior frontal gyrus. At $p<0.0001$, we observed a similar pattern of positive correlations with LEDD mainly located in the frontal and visual networks, with a predominant involvement of interhemispheric connections



CONCLUSIONS

- Chronic dopaminergic therapy enhanced frontal and occipito-parietal FC and inhibited temporo-parietal FC in PD. This finding could explain the influence of the dopaminergic drugs on cognition and mood in PD as well as the appearance of therapy-related side effects.
- On other hand LEDD did not correlate with fronto-striatal FC, which is expected since dopaminergic therapy is mainly augmented to counter the worsening of motor symptoms and thus it probably restores some of the striatal FC lost due to the disease.
- Analysis of functional connectome might add novel insights into the understanding of therapy-related changes and prediction of side effects in PD.